Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV

References

• Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced HIV infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–860.
   PubMed Web of Science ®Google Scholar
• Gandhi M, Gandhi RT. Single-pill regimens for HIV-1 infection. N Engl J Med. 2014;371:1845–1846.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382:1525–1533.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Updated 2016 July 14; cited 2016 Oct 29. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
   Google Scholar
• European AIDS Clinical Society (EACS) Guidelines. Clinical management and treatment of HIV infected adults in Europe. Version 8.1 Oct 2016; cited 2016 Oct 29. Available from: http://www.europeanaidsclinicalsociety.org
   Google Scholar
• AIDS Study Group (GESIDA) of the Spanish Society of Infectious Diseases, Clinical Microbiology, the National AIDS Plan. Executive summary of the GESIDA/national AIDS plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2016). Enferm Infecc Microbiol Clin. 2016;34:439–451.
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA, Reynolds NA, Plosker GL. Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection. Drugs. 2005;65:413–432.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Kirk O, Reiss P, et al.; the EuroSIDA Study Group. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. Aids. 2010;24:1667–1678.
   PubMed Web of Science ®Google Scholar
• Ryom L, Mocroft A, Kirk O, et al.; D:A:D Study Group. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis. 2013;207:1359–1369.
   PubMed Web of Science ®Google Scholar
• McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203:1791–1801.
   PubMed Web of Science ®Google Scholar
• Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26:867–875.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Moore RD. Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS. 2009;23:1971–1975.
   PubMed Web of Science ®Google Scholar
• Mulligan K, Glidden DV, Anderson PL, et al. Preexposure prophylaxis initiative study team. effects of emtricitabine/tenofovir on bone mineral density in HIV-negative persons in a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2015;15(61):572–580.
   Web of Science ®Google Scholar
• Sax PE, Zolopa A, Brar I, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr. 2014;67:52–58.
   PubMedGoogle Scholar
• Lee WA, He GX, Eisenberg E, et al. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother. 2005;49:1898–1906.
   PubMed Web of Science ®Google Scholar
• Ruane PJ, DeJesus E, Berger D, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013;63:449–455.
   PubMed Web of Science ®Google Scholar
• Sax PE, Wohl D, Yin MT, et al.; GS-US-292-0104/0111 Study Team. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385:2606–2615.
   PubMed Web of Science ®Google Scholar
• Mills A, Arribas JR, Andrade-Villanueva J, et al.; GS-US-292-0109 team. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016;16:43–52.
   PubMed Web of Science ®Google Scholar
• Pozniak A, Arribas JR, Gathe J, et al; GS-US-292-0112 Study Team. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase 3 study. J Acquir Immune Defic Syndr. 2016;15(71):530–537.
   Web of Science ®Google Scholar
• Lundgren JD, Babiker AG, Gordin F, et al.; INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV Infection. N Engl J Med. 2015;373:795–807.
   PubMed Web of Science ®Google Scholar
• Cohen MS, Chen YQ, McCauley M, et al.; HPTN 052 Study Team. Antiretroviral therapy for the prevention of HIV-1 Transmission. N Engl J Med. 2016;375:830–839.
   PubMed Web of Science ®Google Scholar
• Sabin CA, Worm SW, Weber R, et al.; D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371:1417–1426.
   PubMed Web of Science ®Google Scholar
• Palella F, Althoff K, Zhang J, et al. Abacavir use and risk for myocardial infarction in the NA-ACCORD. Seattle, Washington: 22nd Conference on retroviruses and opportunistic infections. 2015 Feb 23–26. [abstract 749LB].
   Google Scholar
• Ding X, Andraca-Carrera E, Cooper C, et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr. 2012;61:441–447.
   PubMed Web of Science ®Google Scholar
• Llibre JM, Hill A. Abacavir and cardiovascular disease: a critical look at the data. Antiviral Res. 2016;132:116–121.
   PubMed Web of Science ®Google Scholar
• Birkus G, Wang R, Liu X, et al. Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131. Antimicrob Agents Chemother. 2007;51:543–550.
   PubMed Web of Science ®Google Scholar
• Birkus G, Bam RA, Willkom M, et al. Intracellular activation of tenofovir alafenamide and the effect of viral and host protease inhibitors. Antimicrob Agents Chemother. 2015;60:316–322.
   PubMed Web of Science ®Google Scholar
• Birkus G, Hájek M, Kramata P, et al. Tenofovir diphosphate is a poor substrate and a weak inhibitor of rat DNA polymerases alpha, delta, and epsilon*. Antimicrob Agents Chemother. 2002;46:1610–1613.
   PubMed Web of Science ®Google Scholar
• Callebaut C, Stepan G, Tian Y, et al. In vitro virology profile of tenofovir alafenamide, a novel oral prodrug of tenofovir with improved antiviral activity compared to that of tenofovir disoproxil fumarate. Antimicrob Agents Chemother. 2015;59:5909–5916.
   PubMed Web of Science ®Google Scholar
• Cahn P. Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy. Expert Opin Investig Drugs. 2004;13:55–68.
   PubMed Web of Science ®Google Scholar
• Modrzejewski KA, Herman RA. Emtricitabine: a once-daily nucleoside reverse transcriptase inhibitor. Ann Pharmacother. 2004;38:1006–1014.
   PubMed Web of Science ®Google Scholar
• Frampton JE, Perry CM. Emtricitabine: a review of its use in the management of HIV infection. Drugs. 2005;65:1427–1448.
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Mathias AA, German P, et al. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet. 2011;50:229–244.
   PubMed Web of Science ®Google Scholar
• Deeks ED. Elvitegravir: a review of its use in adults with HIV-1 infection. Drugs. 2014;74:687–697.
   PubMed Web of Science ®Google Scholar
• Mathias AA, German P, Murray BP, et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther. 2010;87:322–329.
   PubMed Web of Science ®Google Scholar
• Deeks ED. Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection. Drugs. 2014;74:195–206.
   PubMed Web of Science ®Google Scholar
• Gilead Sciences Inc. Genvoya_ (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) tablets, for oral use: US elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide: a review 967 prescribing information. 2015. [cited 2016 Oct 29]. Available from: http://www.fda.gov.
   Google Scholar
• Gilead Sciences International Ltd. Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets: EU summary of product characteristics. 2015. [Cited 2016 Oct 29]. Available from: http://www.ema.europa.eu
   Google Scholar
• Bam RA, Yant SR, Cihlar T. Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity. Antivir Ther. 2014;19:687–692.
   PubMed Web of Science ®Google Scholar
• Markowitz M, Zolopa A, Squires K, et al. Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. J Antimicrob Chemother. 2014;69:1362–1369.
   PubMed Web of Science ®Google Scholar
• Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004;43:595–612.
   PubMed Web of Science ®Google Scholar
• Lepist EI, Phan TK, Roy A, et al. Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. Antimicrob Agents Chemother. 2012;56:5409–5413.
   PubMed Web of Science ®Google Scholar
• Ramanathan SWX, Custodio J, Wang H, et al. Pharmacokinetics of a novel EVG/COBI/TFC/GS-7340 single tablet regimen. Paper presented at: 13th International workshop on clinical pharmacology of HIV therapy. Barcelona, Spain: 2012.
   Google Scholar
• Xu L, Liu H, Murray BP, et al. Cobicistat (GS-9350): a potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer. ACS Med Chem Lett. 2010;1:209–213.
   PubMed Web of Science ®Google Scholar
• Shah BM, Schafer JJ, Priano J, et al. Cobicistat: a new boost for the treatment of human immunodeficiency virus infection. Pharmaco- Therapy. 2013;33:1107–1116.
   Web of Science ®Google Scholar
• Nathan B, Bayley J, Waters L, et al. Cobicistat: a novel pharmacoen- hancer for co-formulation with HIV protease and integrase inhibitors. Infect Dis Ther. 2013;2:111–122.
   PubMedGoogle Scholar
• Gaur AH, Kizito H, Prasitsueubsai W, et al. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial. Lancet HIV. 2016;3:e561–e568.
   Google Scholar
• Huhn GD, Tebas P, Gallant J, et al. A randomized, open-label trial to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide plus darunavir in treatment-experienced HIV-1 infected adults. J Acquir Immune Defic Syndr. 2017;74:193–200.
   PubMedGoogle Scholar
• Wohl D, Oka S, Clumeck N, et al.; GS-US-292-0104/0111 and Study Team. Brief report: a randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results. J Acquir Immune Defic Syndr. 2016;72:58–64.
   PubMed Web of Science ®Google Scholar
• Post FA, Tebas P, Clarke A, et al. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected adults with renal impairment: 96-week results from a single-arm, multicenter, open-label phase 3 study. J Acquir Immune Defic Syndr. 2017;74:180–184.
   PubMed Web of Science ®Google Scholar
• Custodio JM, Fordyce M, Garner W, et al. Pharmacokinetics and safety of tenofovir alafenamide in HIV-uninfected subjects with severe renal impairment. Antimicrob Agents Chemother. 2016;60:5135–5140.
   PubMed Web of Science ®Google Scholar
• Margot NA, Johnson A, Miller MD, et al. Characterization of HIV-1 resistance to tenofovir alafenamide in vitro. Antimicrob Agents Chemother. 2015;59:5917–5924.
   PubMed Web of Science ®Google Scholar
• Margot NA, Liu Y, Miller MD, et al. High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate. Antiviral Res. 2016;132:50–58.
   PubMed Web of Science ®Google Scholar
• Margot NA, Kitrinos KM, Fordyce M, et al. Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. HIV Clin Trials. 2016;17:78–87.
   PubMed Web of Science ®Google Scholar
• Gallant J, Brunetta J, Crofoot G, et al.; GS-US-292-1249 Study Investigators. Brief report: efficacy and safety of switching to a single-tablet regimen of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-1/hepatitis B-coinfected adults. J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):294–298.
   PubMed Web of Science ®Google Scholar
• De Clercq E. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochem Pharmacol. 2016 Nov;1(119):1–7.
   Web of Science ®Google Scholar
• Gallant JE, Daar ES, Raffi F, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Lancet HIV. 2016;3:e158–65.
   PubMed Web of Science ®Google Scholar
• Mills A, Crofoot G Jr, McDonald C, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr. 2015;69:439–445.
   PubMed Web of Science ®Google Scholar
• Margolis DA, González-García J, Stellbrink HJ, et al. Cabotegravir+rilpivirine as long-acting maintenance therapy: LATTE-2 week 32 results. 23rd Conference on retroviruses and opportunistic infections, Boston, MA, USA; Feb 22–25, 2016 [ abstract 31LB].
   Google Scholar